UBS Group
JAZZ icon

UBS Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

UBS Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-900
Closed -$115K – 10568
2021
Q4 		$115K Hold
900
– – ﹤0.01% 6184
2021
Q3 		$117K Sell
900
-14,200
-94% -$2.15M ﹤0.01% 5720
2021
Q2 		$2.68M Hold
15,100
– – ﹤0.01% 3290
2021
Q1 		$2.48M Buy
+15,100
New +$2.48M ﹤0.01% 3341
2017
Q1 		– Sell
-50,000
Closed -$5.45M – 7787
2016
Q4 		$5.45M Buy
50,000
+2,500
+5% +$278K ﹤0.01% 2016
2016
Q3 		$5.77M Buy
47,500
+10,000
+27% +$1.35M ﹤0.01% 1893
2016
Q2 		$5.3M Hold
37,500
– – ﹤0.01% 1907
2016
Q1 		$4.9M Sell
37,500
-10,200
-21% -$1.27M ﹤0.01% 1882
2015
Q4 		$6.71M Sell
47,700
-40,000
-46% -$5.54M ﹤0.01% 1721
2015
Q3 		$11.6M Buy
87,700
+45,000
+105% +$7.75M 0.01% 1256
2015
Q2 		$7.52M Buy
42,700
+42,500
+21,250% +$7.63M 0.01% 1704
2015
Q1 		$35K Sell
200
-13,600
-99% -$2.33M ﹤0.01% 6388
2014
Q4 		$2.26M Buy
+13,800
New +$2.29M ﹤0.01% 2783

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

UBS Group's JAZZ Position: Q2 2026 in Review

UBS Group increased its Jazz Pharmaceuticals (JAZZ) stake by 112% in Q2 2026, buying an estimated $87.6M and bringing the position to 756,865 shares worth $182M. The position accounts for 0.02% of the portfolio, ranked #722.

UBS Group first reported a position in JAZZ in Q4 2014 and has held it in 47 quarters since. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • UBS Group held 756,865 shares of Jazz Pharmaceuticals worth $182M as of Q2 2026.
  • UBS Group bought 399,662 Jazz Pharmaceuticals shares in Q2 2026, an estimated $87.6M.
  • Jazz Pharmaceuticals made up 0.02% of UBS Group's portfolio in Q2 2026, its #722 holding.
  • UBS Group first reported a position in Jazz Pharmaceuticals in Q4 2014 and has held it in 47 quarters since.
  • 646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.